Abstract:Multiple myeloma (MM) has witnessed significant therapeutic advancements through the introduction of proteasome inhibitors and immunomodulators, leading to improved treatment outcomes. However, infections remain a formidable challenge for MM patients. The objective of our research is to investigate the factors that can forecast infection risk in MM patients. In pursuit of this, we conducted a thorough retrospective examination of medical records from Kidwai Memorial Institute of Oncology, Bangalore, involving 145 MM patients. Out of the 145 patients analyzed, almost half (47.5%; n = 69) encountered at least one infection during the course of their disease. Respiratory-related infections were the most prevalent (76.2%), followed by urinary tract infections (10%) and instances of diarrhea (8.8%). Notably, gram-positive bacteria constituted the majority of identified causative organisms, accounting for 48.2% of isolated pathogens, while gram-negative bacteria comprised 37.9% of the isolated organisms. Most infections were observed either at the time of presentation or during the first month (40.5%). Overall mortality during the study period was 4.8% ( n = 7). Infections contributed to 57.1% ( n = 4 out of 7 deaths) of the mortality. Moreover, patients in advanced stages exhibited an elevated risk of infection at presentation. Infections remain a major cause of morbidity and mortality in patients with MM. Nearly half of MM patients experience an episode of infection during treatment.Gram-positive bacteria are the most common pathogens, with respiratory infections being the most common foci. Prompt identification and treatment of infections is essential, but can be challenging due to atypical or absent symptoms. Antibacterial prophylaxis is an important preventive strategy, but further research is needed to develop innovative approaches to infection prevention and targeted therapeutic interventions. We must strive to develop innovative approaches to infection prevention in MM patients. Also we need to advance our understanding of the interplay between infections and MM to improve quality of care and outcomes for these individuals. By addressing these challenges, we can aspire to offer MM patients a brighter and healthier future.

Listeria monocytogenes Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma

Sepsis caused by Listeria monocytogenes during chemotherapy for small cell carcinoma of the thymus

Listeria monocytogenes infection associated with alemtuzumab – - a case for better preventive strategies

Disseminated Nontuberculous Mycobacterium Infection During Treatment of Multiple Myeloma: A Case Report and Review of the Literature

Peritoneal dialysis-related Listeria monocytogenes peritonitis treated with both intravenous and intraperitoneal ampicillin

Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management

Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma

Infections during novel myeloma therapies

Drug-Induced Modulation of T Lymphocytes as a Potential Mechanism of Susceptibility to Infections in Patients with Multiple Myeloma During Bortezomib Therapy

Unmasking Infection Risks in Multiple Myeloma: Insights from a Retrospective Analysis

Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study

Fatal Listeria monocytogenes septicemia and meningitis complicated by Candida glabrata fungemia: a case report

Myelotoxicity and kidney dysfunction related to the use of trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia: a case report of severe adverse events with a common drug

Cytomegalovirus Reactivation During Elotuzumab Therapy in Patients with Multiple Myeloma

Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma

A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma

Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma

Severe acute toxoplasmosis infection following ustekinumab treatment in a patient with psoriasis vulgaris

Varicella zoster virus reactivation reported with isatuximab use

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells

Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma